# UnitedHealth Group UNH UNDERVALUED 1.6%

**Buying Index™** 3 **Value Rating** ✓

| Economic Castle | Stock Fair Value Range | Dividend Track Record | Dividend Safety / Cushion™ | Div Growth Potential | Dividend Yield |
|---|---|---|---|---|---|
| Very Attractive | $474.00 - $790.00 | HEALTHY | EXCELLENT / 3.6 | EXCELLENT | 1.80% |

**UnitedHealth Group intends to repurchase a meaningful amount of stock, though its dividend growth outlook remains stellar given its impressive free cash flow generating abilities.**

## Stock Chart (weekly)




## Key Dividend Considerations

| | |
|---|---|
| Current Annual Dividend Yield | **1.80%** |
| Annual Dividends per Share | **$8.40** |
| Initial Annual Div's Paid, $10k Investment | **$180.10** |
| Dividend Track Record | **HEALTHY** |
| Dividend Safety | **EXCELLENT** |
| Valuentum Dividend Cushion™ | **3.6** |
| Dividend Growth Potential | **EXCELLENT** |
| Risk of Capital Loss | **LOW** |
| ValueRisk™ (Equity Margin of Safety) | **MEDIUM** |

The Valuentum Dividend Cushion is a ratio that compares the firm's excess cash and cash flow to its future dividend stream. A score above 1 indicates cash flow is sufficient to cover future dividends (higher is better).

## Dividend Strength

| Dividend Safety \ Dividend Growth | Very Poor | Poor | Good | Excellent |
|---|---|---|---|---|
| Excellent | | | | |
| Good | | | | |
| Poor | | | | |
| Very Poor | | | | |

Firms that have safe and growing dividends score at the top right of our scale.

## Company Vitals

| | |
|---|---|
| Market Cap (USD) | $437,502 |
| Avg Weekly Vol (30 wks) | 19,320 |
| 30-week Range (USD) | 438.5 - 630.73 |
| Valuentum Sector | Health Care |
| Last Fiscal Year Revenue | 371,622 |
| Last Fiscal Year EPS | 23.86 |
| Last Fiscal Year EBITDA | 35,130 |
| Forward Revenue Growth (5-yr) | 7.7% |
| Forward EPS Growth (5-yr) | 9.3% |

## Dividend Vitals

| | |
|---|---|
| Current Annual Dividend Yield % | 1.8% |
| Annual Dividends Per Share | 8.40 |
| Forward Dividend Payout Ratio | 30.4% |
| 3-yr Historical Dividend CAGR | 14.5% |
| 15-yr Historical Dividend CAGR | 45.6% |
| 3-yr Hist Median Div Payout Ratio | 30.6% |
| 15-yr Hist Median Div Payout Ratio | 28.3% |

NMF = Not Meaningful; Est. = Estimated; FY = Fiscal Year

## Initial Annual Income Per Investment ($)

| # of Shares | Investment ($) | Annual Div's ($) |
|---|---|---|
| 25 | 11,660.50 | 210.00 |
| 50 | 23,321.00 | 420.00 |
| 100 | 46,642.00 | 840.00 |
| 200 | 93,284.00 | 1,680.00 |
| 300 | 139,926.00 | 2,520.00 |
| 400 | 186,568.01 | 3,360.00 |
| 500 | 233,210.01 | 4,200.00 |
| 1,000 | 466,420.01 | 8,400.00 |
| 2,000 | 932,840.03 | 16,800.00 |
| 5,000 | 2,332,100.07 | 42,000.00 |
| 10,000 | 4,664,200.13 | 84,000.00 |
| 50,000 | 23,321,001 | 420,000.00 |
| 100,000 | 46,642,001 | 840,000.00 |

Initial annual income is based on the firm's current forward annual dividend yield and could be subject to change.

## Dividend Safety / Cushion — EXCELLENT / 3.6

We assess the safety of a firm's dividend by adding the company's net cash to our forecast of its free cash flows over the next five years. We then divide that sum by the total expected dividends over the next five years. This process results in our Dividend Cushion™ ratio. A Dividend Cushion™ above 1 indicates a firm can cover its future dividends with net cash on hand and future free cash flow, while a score below 1 signals trouble may be on the horizon. And by extension, the greater the score, the safer the dividend, as excess cash can be used to offset any unexpected earnings shortfall. UnitedHealth Group scores a 3.6 on our Dividend Cushion™, which is EXCELLENT.

## Dividend Growth Potential — EXCELLENT

We judge the future potential growth of the dividend by evaluating the capacity for future increases, as measured by the Dividend Cushion™, and management's willingness to consistently raise the dividend, as measured by the firm's dividend track record. UnitedHealth Group registers an EXCELLENT rating on our scale, and we think the firm's annual dividend will be $13.94 per share within the next several years.

## Risk of Capital Loss — LOW

We assess the risk of capital loss based on our analysis of a firm's intrinsic value at this point in time. If the stock is undervalued (based on our DCF process), we think the risk of failing to recoup one's original capital investment (ex dividends) is relatively LOW. If the stock is fairly valued (it falls within our fair value estimate range), we think the likelihood of losing capital (ex dividends) is MEDIUM. If the stock is trading above our estimate of its intrinsic value, we think the likelihood of losing at least a portion of one's original investment (ex dividends) is HIGH. UnitedHealth Group registers a score of LOW on our scale.

## Dividend Track Record — HEALTHY

| Fiscal Year | Div's/Share ($) | Div Growth % | EPS ($) | Payout Ratio |
|---|---|---|---|---|
| Dec-09 | 0.03 | 0.0 | 3.24 | 0.9% |
| Dec-10 | 0.41 | 1266.7 | 4.10 | 10.0% |
| Dec-11 | 0.61 | 48.8 | 4.73 | 12.9% |
| Dec-12 | 0.80 | 31.1 | 5.28 | 15.2% |
| Dec-13 | 1.05 | 31.3 | 5.50 | 19.1% |
| Dec-14 | 1.41 | 34.3 | 5.70 | 24.7% |
| Dec-15 | 1.88 | 33.3 | 6.01 | 31.3% |
| Dec-16 | 2.38 | 26.6 | 7.25 | 32.8% |
| Dec-17 | 2.88 | 20.8 | 10.72 | 26.8% |
| Dec-18 | 3.45 | 20.0 | 12.19 | 28.3% |
| Dec-19 | 4.14 | 20.0 | 14.33 | 28.9% |
| Dec-20 | 4.83 | 16.7 | 16.03 | 30.1% |
| Dec-21 | 5.60 | 15.9 | 18.08 | 31.0% |
| Dec-22 | 6.40 | 14.3 | 21.18 | 30.2% |
| Dec-23 | 7.29 | 13.9 | 23.86 | 30.6% |
| ***Dec-24*** | ***8.40*** | ***15.2*** | ***27.66*** | ***30.4%*** |
| *Dec-25* | *9.66* | *15.0* | *30.07* | *30.4%* |
| *Dec-26* | *11.11* | *15.0* | *32.66* | *30.4%* |
| *Dec-27* | *12.44* | *12.0* | *35.10* | *30.4%* |
| *Dec-28* | *13.94* | *12.0* | *37.30* | *30.4%* |

Light green shading denotes a dividend increase, while light red shading denotes a dividend decrease. Heavy green shading denotes a significant dividend increase, while heavy red shading denotes a significant dividend decrease or an excessive payout ratio. NA = Not Applicable.

To view our full 16-page equity report on UnitedHealth Group, please visit our website at www.valuentum.com

The information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at valuentum@valuentum.com.

# UnitedHealth Group UNH UNDERVALUED 1.6%

**Buying Index™** 3 **Value Rating** ✓

| Economic Castle | Stock Fair Value Range | Dividend Track Record | Dividend Safety / Cushion™ | Div Growth Potential | Dividend Yield |
|---|---|---|---|---|---|
| Very Attractive | $474.00 - $790.00 | HEALTHY | EXCELLENT / 3.6 | EXCELLENT | 1.80% |

## Assessment of Company Dividend Strategy

**Key Strengths**

There is a whole lot to like about UnitedHealth, as the largest insurance provider in the US with two primary business platforms: 'UnitedHealthcare' (provides health benefits) and 'Optum' (for health services). Its Optum businesses have been a source of strength in recent years, and we expect strong expansion to continue. From 2021 to 2023, UnitedHealth's annual free cash flows averaged ~$23 billion while its annual run-rate dividend obligations stood at ~$6.8 billion in 2023. UnitedHealth's Dividend Cushion ratio is impressive, and we expect the firm will push through aggressive annual dividend increases in the coming years.

**Potential Weaknesses**

As UnitedHealth's impressive Dividend Cushion ratio suggests, finding cracks in its dividend profile is not easy. Acquisitions will remain an important part of the company's growth strategy (its goodwill balance is significant), as it continues to scoop up assets (selection and overpayment risk are high). However, we are pleased with UnitedHealth's deal making in light of portfolio benefits and strong incremental free cash flow generation. Competition from other companies including Aetna, Anthem and Cigna pose threats. Additionally, share repurchases will compete for capital going forward.

## Graphical Relationship, Earnings and Dividends (per share)




The graph above shows the relationship between a firm's earnings per share and its dividends per share.

## Dividend Cushion Cash Flow Bridge Evaluation

The Dividend Cushion Cash Flow Bridge, shown in the image to the right, illustrates the components of the Dividend Cushion ratio and highlights in detail the many drivers behind it. UnitedHealth Group's Dividend Cushion Cash Flow Bridge reveals that the sum of the company's 5-year cumulative free cash flow generation, as measured by cash flow from operations less all capital spending, plus its net cash/debt position on the balance sheet, as of the last fiscal year, is greater than the sum of the next 5 years of expected cash dividends paid. Because the Dividend Cushion ratio is forward-looking and captures the trajectory of the company's free cash flow generation and dividend growth, it reveals whether there will be a cash surplus or a cash shortfall at the end of the 5-year period, taking into consideration the leverage on the balance sheet, a key source of risk. On a fundamental basis, we believe companies that have a strong net cash position on the balance sheet and are generating a significant amount of free cash flow are better able to pay and grow their dividend over time. Firms that are buried under a mountain of debt and do not sufficiently cover their dividend with free cash flow are more at risk of a dividend cut or a suspension of growth, all else equal, in our opinion. Generally speaking, the greater the 'blue bar' to the right is in the positive, the more durable a company's dividend, and the greater the 'blue bar' to the right is in the negative, the less durable a company's dividend.

## Dividend Cushion Cash Flow Bridge




Source: Company Filings, Valuentum Projections

## Dividend Cushion Ratio Evaluation

The Dividend Cushion Ratio Deconstruction, shown in the image to the right, reveals the numerator and denominator of the Dividend Cushion ratio. At the core, the larger the numerator, or the healthier a company's balance sheet and future free cash flow generation, relative to the denominator, or a company's cash dividend obligations, the more durable the dividend. In the context of the Dividend Cushion ratio, UnitedHealth Group's numerator is larger than its denominator suggesting strong dividend coverage in the future. The Dividend Cushion Ratio Deconstruction image puts sources of free cash in the context of financial obligations next to expected cash dividend payments over the next 5 years on a side-by-side comparison. Because the Dividend Cushion ratio and many of its components are forward-looking, our dividend evaluation may change upon subsequent updates as future forecasts are altered to reflect new information.

## Dividend Cushion Ratio Deconstruction




The information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at valuentum@valuentum.com.

# Definitions, Disclosures, Disclaimers & Additional Sources

**Fair Value Range.** The fair value range represents an upper bound and lower bound, between which we would consider the firm to be fairly valued. The range considers our estimate of the firm's fair value and the margin of safety suggested by the volatility of key valuation drivers, including revenue, gross margin, earnings before interest, and enterprise free cash flow (the determinants behind our ValueRisk™ rating).

**ValueRisk™.** This is a proprietary Valuentum measure. ValueRisk™ indicates the historical volatility of key valuation drivers, including revenue, gross margin, earnings before interest, and enterprise free cash flow. The standard deviation of each measure is calculated and scaled against last year's measure to arrive at a percentage deviation for each item. These percentage deviations are weighted equally to arrive at the corresponding fair value range for each stock, measured in percentage terms. The firm's performance is measured along the scale of LOW, MEDIUM, HIGH, and VERY HIGH. The ValueRisk™ rating for each firm also determines the fundamental beta of each firm along the following scale: LOW (0.85), MEDIUM (1), HIGH (1.15), VERY HIGH (1.3).

**Dividend Track Record.** We assess each firm's dividend track record based on whether the fundamentals of the firm have ever forced it to cut its dividend. If the firm has ever cut its dividend (within the last 10 years), we view its track record as RISKY. If the firm has maintained and/or raised its dividend each year (over the past 10 years), we view its track record as HEALTHY.

**Dividend Safety.** We measure the safety of a firm's dividend by adding its net cash to our forecast of its future cash flows and divide that sum by our forecast of its future dividend payments. This process results in a ratio called the Dividend Cushion™. Scale: Above 2.75 = EXCELLENT; Between 1.25 and 2.75 = GOOD; Between 0.5 and 1.25 = POOR; Below 0.5 = VERY POOR.

**Valuentum Dividend Cushion™.** This is a proprietary Valuentum measure that drives our assessment of the firm's Dividend Safety rating. The forward-looking measure assesses dividend coverage via the cash characteristics of the business.

**Dividend Growth Potential.** We blend our analysis of a firm's Dividend Safety with its historical Track Record, while also considering historical dividend growth trends. We believe such a combination captures a firm's capacity (cash flow) and willingness (track record) to raise its dividend in the future. Scale: EXCELLENT, GOOD, POOR, VERY POOR.

**Risk of Capital Loss**. We think capital preservation is key for the dividend investor. As such, we evalute the risk of capital loss by assessing the intrinsic value of each firm based on our discounted cash-flow process. If a firm is significantly OVERVALUED, we think the risk of capital loss is HIGH. If a firm is FAIRLY VALUED, we think the risk of capital loss is MEDIUM, and if a firm is UNDERVALUED, we think the risk of capital loss is LOW.

**Dividend Strength.** Our assessment of the firm's dividend strength is expressed in a matrix. If the safety of a firm's dividend is EXCELLENT and its growth prospects are also EXCELLENT, it scores high on our matrix (top right). If the firm's dividend safety and the potential future growth are VERY POOR, it scores lower on our scale (bottom left).

The High Yield Dividend Newsletter portfolio, the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Any performance, including that in the Nelson Exclusive publication, is hypothetical and does not represent actual trading. Past performance is not a guarantee of future results. Valuentum is an investment research publishing company.

Valuentum has not owned and does not own any shares of stocks mentioned on its website or in this report. President of Investment Research Brian Nelson does not own any shares of stocks mentioned on Valuentum's website or in this report. Majority share owner of Valuentum, Elizabeth Nelson, currently has exposure to HON in her retirement account. If an independent contributor or employee mentions a stock he or she owns, we disclose it in the article/report that mentions the security. Please view individual articles on Valuentum's website for additional disclosures. Contact us to learn more about Valuentum's editorial policies.

Dividend Methodology Note: For oil and gas pipeline firms, which operate different business structures, and utilities (including waste firms) we employ a different methodology such that comparisons with general operating firms remain meaningful. For oil and gas pipeline firms, we add equity issuance in the future to the numerator and use 0.2 of the firm's total debt load. For utilities, we use 0.5 of the firm's total debt load.

Copyright (c) 2021 by Valuentum, Inc. All rights reserved.
No part of this publication may be reproduced in any form or by any means.
The information contained in this report is not represented or warranted to be accurate, correct, complete, or timely. This report is for informational purposes only and should not be considered a solicitation to buy or sell any security. No warranty or guarantee may be created or extended by sales or promotional materials, whether by email or in any other format. The securities or strategies mentioned herein may not be suitable for all types of investors. The information contained in this report does not constitute any advice, especially on the tax consequences of making any particular investment decision. This material is not intended for any specific type of investor and does not take into account an investor's particular investment objectives, financial situation or needs. This report is not intended as a recommendation of the security highlighted or any particular investment strategy. Before acting on any information found in this report, readers should consider whether such an investment is suitable for their particular circumstances, perform their own due-diligence, and if necessary, seek professional advice.
The sources of the data used in this report are believed by Valuentum to be reliable, but the data's accuracy, completeness or interpretation cannot be guaranteed. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report and accepts no liability for how readers may choose to utilize the content. In no event shall Valuentum be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the information contained in this document. Investors should consider this report as only a single factor in making their investment decision.
Valuentum is not a money manager, is not a registered investment advisor, and does not offer brokerage or investment banking services. Valuentum has not received any compensation from the company or companies highlighted in this report. Valuentum, its employees, independent contractors and affiliates may have long, short or derivative positions in the securities mentioned herein. Information and data in Valuentum's valuation models and analysis may not capture all subjective, qualitative influences such as changes in management, business and political trends, or legal and regulatory developments. Redistribution is prohibited without written permission. Readers should be aware that information in this work may have changed between when this work was written or created and when it is read. There is risk of substantial loss associated with investing in financial instruments.
Valuentum's company-specific forecasts used in its discounted cash flow model are rules-based. These rules reflect the experience and opinions of Valuentum's analyst team. Historical data used in our valuation model is provided by Xignite and from other publicly available sources including annual and quarterly regulatory filings. Stock price and volume data is provided by Xignite. No warranty is made regarding the accuracy of any data or any opinions. Valuentum's valuation model is based on sound academic principles, and other forecasts in the model such as inflation and the equity risk premium are based on long-term averages. The Valuentum proprietary automated text-generation system creates text that will vary by company and may often change for the same company upon subsequent updates.
Valuentum uses its own proprietary stock investment style and industry classification systems. Peer companies are selected based on the opinions of the Valuentum analyst team. Research reports and data are updated periodically, though Valuentum assumes no obligation to update its reports, opinions, or data following publication in any form or format. Performance assessment of Valuentum metrics, including the Valuentum Buying Index, is ongoing, and we intend to update investors periodically, though Valuentum assumes no obligation to do so. Not all information is available on all companies. There may be a lag before reports and data are updated for stock splits and stock dividends.
Past simulated performance, whether backtested or walk-forward or other, is not a guarantee of future results. For general information about Valuentum's products and services, please contact us at valuentum@valuentum.com or visit our website at www.valuentum.com.

# Appendix A: About Valuentum

@Valuentum, we strive to stand out from the crowd. Most investment research publishers fall into a few camps, whether it be value, growth, income, momentum, chartist or some variant of the aforementioned. We think each in its own right holds merit, but we think the combination of these approaches can be even more powerful. After all, stock price movements aren't just driven by investors of the value or growth variety, but by all market participants. Therefore, we look at stocks from a variety of investment perspectives in order to better understand and identify ideas. We want to provide relevant information.

The core of our process is grounded in rigorous discounted cash flow analysis and incorporates the concept of a margin of safety. We offer a fair value estimate for each company and provide a relative valuation assessment in the context of a company's industry and closest peers. A cross section of our ValueCreation™ and ValueRisk™ ratings provides a financial assessment of a company's business quality, while our ValueTrend™ rating offers insight into the trajectory of a firm's economic profit creation. The Economic Castle rating measures the magnitude of future economic value generation, and the Dividend Cushion ratio assesses the financial capacity of a company to keep raising its dividend.

Our analysis doesn't stop there. We also offer a technical evaluation of the stock as well as other momentum indicators. We not only want to reveal to readers which firms may be undervalued, in our view, but we also want to provide readers with information to help them assess entry and exit points. Most research publishers focus on arriving at a target price or fair value estimate, but may fall short of providing a technical assessment to bolster buy and sell disciplines. We strive to go the distance and provide readers with answers--not half the story.

An explanation of our approach would not be complete if we didn't describe our ideal stock idea. We're looking for companies that are undervalued--both on a DCF basis and versus peers--have strong growth potential, have a solid track record of creating economic profits for shareholders with reasonable risk, are strong cash flow generators, have manageable financial leverage, and are currently showing bullish technical and momentum indicators. For dividend growth ideas, we look for companies that have both the capacity and willingness to keep raising the dividend.

Can such stock ideas exist? Subscribe to Valuentum to receive our best investment ideas and analysis on over one hundred stocks, dividends, ETFs and more.




The information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at valuentum@valuentum.com.

# Appendix B: Methodology for Picking Stocks - Valuentum Buying Index™ (VBI)

@ Valuentum, we like to look at companies from a number of different perspectives. The Valuentum Buying Index (VBI) combines rigorous financial and valuation analysis with an evaluation of a stock's technicals to derive a rating between 1 and 10 for each company. The VBI places considerable emphasis on a company's discounted cash-flow (DCF) valuation, its relative valuation versus peers (both forward PE and PEG ratios), and its technicals in order to help readers assess entry and exit points on the most interesting ideas.

Let's follow the red line on the flow chart below to see how a company can score a 10, the best mark on the index. First, the company would need to be 'undervalued' on a DCF basis and 'attractive' on a relative value basis. The stock would also have to be exhibiting 'bullish' technicals. The firm would need a ValueCreation™ rating of 'good' or 'excellent', exhibit 'high' or 'aggressive' growth prospects, and generate at least a 'medium' or 'neutral' assessment for cash flow generation, financial leverage, and relative price strength.

This is a tall order for any company. Stocks that don't make the cut for a 10 are ranked accordingly, with the least attractive stocks, in our opinion, garnering a rating of 1. Most of our coverage universe registers ratings between 3 and 7, but at any given time there could be large number of companies garnering either very high or very low scores, especially at market lows or tops, respectively.

The Best Ideas Newsletter portfolio puts the VBI into practice.




| VBI Score | Consideration |
|---|---|
| 10 | Top Idea |
| 9 | Strong Idea |
| 6 to 8 | Constructive |
| 3 to 6 | Less Exciting |
| 1 to 2 | Poor Idea |

The information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at valuentum@valuentum.com.